Palatin Technologies Stockholders Approve Key Governance Changes

Palatin Technologies ( (PTNT) ) has issued an update.

On July 25, 2025, Palatin Technologies held its annual meeting of stockholders to vote on several key issues, including the election of directors and an amendment to effect a reverse stock split. The stockholders approved the election of four directors and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2025. Additionally, they approved the issuance of shares upon the exercise of certain stock purchase warrants and an amendment to increase the number of shares available for equity awards. These decisions are expected to impact the company’s financial structure and governance, potentially affecting its market positioning and stakeholder interests.

The most recent analyst rating on (PTNT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Palatin Technologies stock, see the PTNT Stock Forecast page.

Spark’s Take on PTNT Stock

According to Spark, TipRanks’ AI Analyst, PTNT is a Underperform.

Palatin Technologies faces severe financial difficulties, with negative equity and reliance on external financing. The technical indicators suggest potential short-term momentum, but the valuation remains unattractive due to persistent losses. Additionally, the risk of NYSE delisting further exacerbates the company’s challenges, contributing to a low overall score.

To see Spark’s full report on PTNT stock, click here.

More about Palatin Technologies

Palatin Technologies, Inc. operates in the biopharmaceutical industry, focusing on developing targeted receptor-specific therapeutics for the treatment of diseases with significant unmet medical needs.

Average Trading Volume: 883,462

Technical Sentiment Signal: Strong Sell

Current Market Cap: $10.04M

See more insights into PTNT stock on TipRanks’ Stock Analysis page.